Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133928) titled 'A prospective clinical study evaluating the efficacy and safety of all-trans retinoic acid combined with the IDH1 inhibitor ivosidenib in IDH1-mutated MDS' on Oct. 9.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Condition:
Myelodysplastic Syndrome (MDS)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10-20
Target Sample Size: Treatment Group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=345699
Disclaimer: Curated by ...